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Abstract
Background: Type 2 diabetes mellitus is a chronic progressive disease. During the course of the disease intensive
treatment is often necessary resulting in multiple interventions including administration of insulin. Although dietary
intervention is highly recommended, the clinical results of the widely prescribed diets with low fat content and
high carbohydrates are disappointing. In this proof-of-concept study, we tested the effect of dietary carbohydrate-
restriction in conjunction with metformin and liraglutide on metabolic control in patients with type 2 diabetes.
Methods: Forty patients with type 2 diabetes already being treated with two oral anti-diabetic drugs or insulin
treatment and who showed deterioration of their glucose metabolism (i.e. HbA1c >7.5), were treated. A
carbohydrate-restricted diet and a combination of metformin and liraglutide were instituted, after stopping either
insulin or oral anti-diabetic drugs (excluding metformin). After enrollment, the study patients were scheduled for
follow-up visits at one, two, three and six months. Primary outcome was glycemic control, measured by HbA1c at
six months. Secondary outcomes were body weight, lipid-profile and treatment satisfaction.
Results: Thirty-five (88%) participants completed the study. Nearly all participating patients experienced a drop in
HbA1c and body weight during the first three months, an effect which was maintained until the end of the study at six
months. Seventy-one percent of the patients reached HbA1c values below 7.0%. The range of body weight at
enrollment was extreme, reaching 165 kg as the highest initial value. The average weight loss after 6 months was 10%.
Most patients were satisfied with this treatment. During the intervention no significant change of lipids was observed.
Most patients who were on insulin could maintain the treatment without insulin with far better metabolic control.
Conclusions: Carbohydrate restriction in conjunction with metformin and liraglutide is an effective treatment
option for patients with advanced diabetes who are candidates for instituting insulin or who are in need of
intensified insulin treatment. This proof-of-principle study showed a significant treatment effect on metabolic
control.
Background
Diabetes and obesity are closely linked diseases with ris-
ing prevalence and incidence in developed and develop-
ing countries [1]. Westernized eating habits and lifestyle
are presumed to be the major reasons for this epidemic.
Official guidelines recommend diets with low fat contents
and high amounts of carbohydrates although it has never
been proven that these are effective in reducing cardio-
vascular disease morbidity and mortality, the major
health problems connected with diabetes and obesity [2].
Recently the Women’s Health Initiative study showed no
effect of a diet restricted in fat content and enriched in
carbohydrates on cardiovascular morbidity and mortality
[3]. Reducing body weight is considered an important
therapeutic intervention to treat patients with type
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tings. Most intervention trials have failed to demonstrate
a long lasting effect. Putting patients on insulin will often
cause an increase in body weight resulting in the need for
further insulin to be injected. Although many patients are
on high insulin doses, metabolic results are often poor
with high HbA1c values. The standard low fat-high car-
bohydrate intervention has been challenged as proper
interventions in obese patients and avoiding “fattening”
carbohydrates is recommended as a strong alternative
therapeutic option.
Historically, there has been a scientific tradition favoring
dietary carbohydrate-restriction in obese patients in Eur-
ope before the Second World War [4] and in the Fifties in
the USA [5]. The recently published A to Z trial showed
that the most beneficial effect in weight reduction was in
those patients treated with a carbohydrate-restricted diet
in comparison with three other dietary interventions,
lower in fat and higher in carbohydrates [6]. There may be
individual differences, some patients doing better on a car-
bohydrate-restricted diet to reduce weight while others do
better on a fat-restricted diet. A possible explanation
might be a different insulin response after a glucose chal-
lenge, i.e. a high response reflecting insulin resistance [7],
in those patients that did better on a carbohydrate-
restricted diet.
In addition, diets that are rich in carbohydrates will
result in an unfavorable cardiovascular risk profile result-
ing in raised triglycerides and lowered HDL and increased
small dense LDL [8]. Glycemic index of carbohydrates is a
strong determinant of HDL-cholesterol concentration in
plasma [9]. In context of carbohydrate-restriction, dietary
saturated fat has also been shown to exhibit a beneficial
effect on plasma lipids [10]. These latter conditions are
neglected in official recommendations. A recent review of
the scientific evidence of dietary carbohydrate-restriction
in type 2 diabetes challenged the official recommendation
of low fat diets [11]. The beneficial effect of a low-carbo-
hydrate, ketogenic diet versus a low-glycemic index caloric
restricted diet improved metabolic control in patients with
type 2 diabetes and also resulted in greater weight loss and
reduction or complete cessation of anti-diabetic medica-
tions [12]. A two year randomized trial comparing low
carbohydrate diet versus low fat diet in obese patients did
also show a more favorable lipid profile in those patients
randomized to the low carbohydrate diet treatment [13].
The recently introduced GLP-1 analogues have expanded
our possible therapeutic options for type 2 diabetes. It has
been shown that these analogues, e.g. exenatide and lira-
glutide, are effective in reducing metabolic outcomes used
alone or in combination with oral drugs. It was also shown
that liraglutide was as effective as glargine insulin in redu-
cing HbA1c [14]. Bypassing glucose- dependent endogen-
ous insulin stimulation, thus avoiding hypoglycemia, is an
important effect of this new class of drugs. In addition to
stimulation of insulin release, one major effect of all GLP-1
analogues is the induction of satiety by delaying gastric
output. This will facilitate weight reduction, which has
been shown for obese non diabetic patients in an interven-
tion trial [15].
Methods
Study-design
This study was a 24 weeks multi-center intervention trial,
designed as proof-of-concept study without control group.
Five medical offices specializing in diabetes care partici-
pated in this study after training in the concept of carbo-
hydrate restricted diets and introduction to the
educational material to be given to patients. The trial was
conducted between 1 September 2010 and 31 July 2011.
This trial was conducted in accordance with International
Conference on Harmonization guidelines and the Declara-
tion of Helsinki and Good Clinical Practice guidelines [16].
Participants
Forty ambulatory patients with type 2 diabetes showing
unsatisfactory metabolic control of their glucose metabo-
lism, who were either already on two antidiabetic drugs
and were scheduled to switch to insulin treatment or
who were already on insulin treatment, but were sched-
uled for intensification of therapy, were included in this
study. The inclusion of patients was up to the choice of
the participating medical offices. Inclusion criteria were
confirmed type 2 diabetes mellitus, HbA1c >7.5% and
BMI above 30 kg/m
2. Exclusion citeria were significant
co-morbid diseases such as kidney disease with glomeru-
lar filtration rate below 60 ml or liver disease (AST or
ALT twice above the upper normal range). There were
no incentives paid to the patients.
Intervention
The patients were introduced to this treatment option and
gave informed written consent. After being selected, basic
anthropometric measures, i.e. body weight, height and age,
were recorded. Basic anamnestic questions regarding
duration of diabetes and cardiovascular diseases were
asked. Routine laboratory values were taken at study entry.
Participants were taught about the principles of carbohy-
drate restriction diets, received an educational booklet and
were trained to inject liraglutide. During the first 2 months
patients were counseled to adhere to this diet, which con-
tained less than 20 grams of carbohydrates per day but
was unrestricted with respect to calories. After 8 weeks
patients were allowed to add small amounts of carbohy-
drates for breakfast. The starting dose of liraglutide was
0.6 mg/day with adjustment to 1.2 mg after one week until
the first control visit four weeks later. Further adjustments
were the decision of the participating physician.
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follow-up visits after 1, 2, 3 and 6 months. At all follow up
visits laboratory control values including blood glucose,
HbA1c, lipids and creatine were measured. Body weight
was estimated to the nearest kg. At each visit a physician
reviewed the blood glucose values and discussed adjust-
ment of medications.
Participants Satisfaction with the treatment
During the follow up visits and at the end of the 6-month
intervention period, participants could comment on treat-
ment satisfaction in a questionnaire using a 7-point Likert
scale. Questions addressed the overall satisfaction with the
treatment, weight loss, blood glucose values, the avoidance
of carbohydrates and the issue of staying on a low-carb
diet. The issue of importance to avoid insulin treatment
and avoiding carbohydrates for breakfast, lunch and din-
ner was evaluated on a 5-point scale separately. The scales
were coded 1 = strongly disagree going up to 7 = comple-
tely agree for the 7 point scale and 1 = not important at all
to 5 = very important for the 5 point scale.
Statistical analysis
All data were collected anonymously in a data base in the
coordinating study center using Epi Info version 3.5.3 for
data management http://www.cdc.gov/epiinfo. All statisti-
c a la n a l y s e sw e r ed o n eu s i n gS A S9 . 0( S A SI n s t i t u t eI n c ,
Cary, North Carolina) or R software version 2.92 (R Foun-
dation for Statistical computing, http://www.r-project.org.
Analysis of continuous outcome data was done taking
repeated measurements into account by using multilevel
modeling. Because of unequal intervals between follow up
visits, time was additionally used as categorical variable. In
addition, analysis of continuous outcome data were done
by imputing missing values under the assumption of last
observations carried forward (LOCF). P-values <0.05 were
considered to be significant. Additionally primary outcome
w a sa n a l y z e du s i n gap a i r e dt - t e s to rW i l c o x o nt e s ta s
appropriate comparing baseline value and 24-weeks value
in complete cases.
Role of funding source
The study was not funded by external sources. No
potential conflicts of interest relevant to this article are
reported.
Results
Participants
40 patients were initially found eligible for study and
agreed to participate. There were 5 drop-outs: One patient
did not come to the first follow up visit for unknown rea-
sons and could not be contacted, two people were not
able to stay on the diet and two people had to switch back
to insulin because of deterioration of blood glucose,
leaving 35 patients to be included in the study. 24 patients
of the initial cohort were on oral anti-diabetic medication
and 16 patients were on insulin. The baseline characteris-
tics of the entire group are shown in Table 1. In Table 1,
patients are divided into those on oral drugs or on insulin.
There was no difference in age between the two groups.
Twenty-three patients were male and 17, female. As
expected, duration of diabetes was different between these
two groups. The mean duration was 10.3 years in the insu-
lin-treated group and 5.7 years in the group treated with
oral anti-diabetic medication.
Outcomes
Hemoglobin A1c
The average baseline HbA1c was 9.0% for the entire
group. The insulin treated group showed a HbAc1 of
8.5%, lower than the HbA1c value for the oral medica-
tion-treated patients whose mean HbA1c was 9.5%
(Table 1).
As shown in Figure 1, there was a drop of mean
HbA1c from baseline value of 9.0% to 6.7% at 24 weeks
for the group as a whole (9.0% ± 1.2 to 6.7 ± 0.8%, p <
0.0001, within group change). The individual time
course of HbA1c values during the study showed a con-
sistent fall in all but two study participants (Figure 2).
The initial HbA1c for insulin treated patients dropped
from 8.5% ± 0.8% to 6.7 ± 0.7%, p < 0.0001 at 24 weeks
and from 9.5% ± 1.3% to 6.7 ± 0.9%, p < 0.0001 for
patients on oral drugs (Table 2). The average decline in
HbA1c was nearly superimposable at 2, 3 and 6 months
(Figure 3). The absolute drop of HbA1c was greater for
patients who had been on oral drugs in comparison to
the group who had been on insulin, 2.8% versus 1.8%.
In a multilevel model describing HbA1c as dependent
variable, the predictor time was highly significant at all
time points (p < 0.0001), using time as categorical vari-
able (drop of HbA1c at: Visit 4 = -2.3308, Visit 3 =
-2.3583, Visit 2 = -2.0816, Visit 1 = -1.2916) or as con-
tinuous variable (drop of HbA1c per time unit =
-0.5964). The model with best fit to the data was
derived using a random intercept and random slope
model. The addition of gender to the model showed no
significant effect, but adding insulin resulted in a mar-
ginally significant interaction term time*insulin -0.2255
(p = 0.047).
Body weight
The mean initial body weight was 116.1 kg with a wide
range going up to 165 kg. During the time course of the
intervention the mean body weight at 24 weeks dropped
significantly to 101.3 ± 17.8 kg, p < 0.0001. The drop in
body weight in patients who had been on insulin before
was greater in comparison with the patient who had
been on oral drugs, 115.6 ± 22.0 kg to 94.7.0 ± 17.5 kg
versus 116.4 ± 19.5 to 105.3 ± 17.1 kg.
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During the time course of the intervention there were no
significant changes in any of the lipid parameters analyzed
(Table 2). In particular, there was no increase in LDL-cho-
lesterol. After splitting the patient group according to pre-
treatment, there were also no significant differences in any
lipid parameters in the two groups (Table 3). The indivi-
dual time course of triglycerides during the study as
shown in Figure 4 exhibited a consistent decline. Three
patients showed an increase of their triglycerides between
the 3rd and 4th follow up visit.
Treatment satisfaction
The majority of patients accepted the new treatment
option as shown in Table 4. Allmost all patients indicated
strong treatment satisfaction on the Likert scale with
respect to blood glucose values and body weight. Restric-
tion of carbohydrates in conjunction with liraglutide and
metformin treatment, offering thereby the option to avoid
Table 1 Baseline characteristics of participants
Whole Group n = 40 Insulin Group n = 16 OAD † Group n = 24
Mean SD Mean SD Mean SD
HbA1c 9.0 1.2 8.5 0.8 9.5 1.3
Body weight, kg 116.1 20.2 115.6 22.0 116.4 19.5
Age years 57.1 9.6 56.8 9.7 57.4 9.8
Diabetes Duration 7.5 6.1 10.3 7.8 5.7 3.9
Cholesterol 209.1 44.8 210.0 46.0 208.5 45.1
Triglycerides 254.7 123.5 263.4 118.7 248.9 129.2
HDL-cholesterol 49.5 18.5 47.1 11.6 51.1 22.1
LDL-cholesterol 119.0 35.9 119.6 38.9 118.4 40.1
†OAD: Oral Antidiabetic Drug
Figure 1 Time course of HbA1c. This figure displays the drop of HbA1c during the intervention at all visits until the end of the study at 6
months.
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patients.
Medication changes
According to the study protocol, all patients were on
two oral anti-diabetic drugs or on insulin at baseline.
Table 5 shows the changes in medications for those
patients who were taking insulin at baseline. 13 patients
out of 14 insulin-treated patients who completed the
study were able to stop insulin, including those who had
been on large doses of insulin; one patient had been
injecting 300 insulin units per day.
Discussion
HbA1c, which reflects cumulative metabolic control dur-
ing the previous three months, is considered to be the
most important predictor for microvascular outcomes.
This was shown for type 1 diabetes as well as for type 2
diabetes [17,18]. The impact of metabolic control of
blood glucose on macrovascular outcomes is a matter of
debate. The results of the recent published ACCORD
Trial showed no benefit with respect to mortality for
patients with type 2 diabetes with a traget of HbA1c
below 6 [19]. Because patients with type 2 diabetes
Figure 2 Trajectories of HbA1c in individual patients. The pattern in this figure is concerned with individual changes of HbA1c during the
intervention. Each line displays the individual change of HbA1c.
Table 2 Effect of treatment program on glycemic control, body weight and plasma lipids
Week 0
Mean ± SD
Week 4
Mean ± SD
Week 8
Mean ± SD
Week 12
Mean ± SD
Week 24
Mean ± SD
HbA1c 9.0 ± 1.2 7.8 ± 0.8 6.9 ± 0.8 6.6 ± 0.7 6.7 ± 0.8 †
Weight 116.1 ± 20.2 109.9 ± 18.2 108.9 ± 19.0 104.6 ± 17.2 101.3 ± 17.8 †
Cholesterol 209.1 ± 44.8 197.6 ± 41.3 195.7 ± 39.0 197.6 ± 35.0 193.0 ± 32.7 ‡
Triglycerides 254.7 ± 123.5 206.3 ± 77.5 194.5 ± 60.5 198.3 ± 63.5 198.8 ± 92.6 ‡
HDL-cholesterol 49.5 ± 18.5 46.9 ± 17.1 49.7 ± 17.3 51.9 ± 16.9 54.0 ± 17.6 ‡
LDL-cholesterol 119.0 ± 38.9 108.9 ± 32.2 110.8 ± 31.9 107.6 ± 31.6 101.1 ± 29.3 ‡
†p < 0.0001 versus baseline
‡p >0.05 versus baseline
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tant to reach metabolic control with few side effects and
low risk of hypoglycemia. People on anti-diabetic drugs
will often gain body weight, further increasing risk for
cardiovasuclar disease. This is especially true of insulin.
In our study, using a combined approach of low-carbohy-
drate diet in combination with metformin and the novel
substance liraglutide patients were able to achieve meta-
bolic control; seventy-one percent of patients attained a
HbA1c below 7.0%. In absolute terms, there was a drop
in mean HbA1c from 9.0% to 6.7%. This is far greater
than that attained by other treatment options. Most anti-
diabetic oral drug treatment options will reduce HbA1c
by about 1% [20]. Although insulin is claimed to have the
strongest effect on metabolic control, results even with
large amounts are often disappointing. The patients in
this study, who were already on insulin - some patients
injecting more than 150 U/day - were able to stop insulin
while maintaining a level of metabolic control compar-
able to that in the group without insulin pretreatment.
This is quite remarkable because, according to base line
data, the duration time of diabetes in the insulin pre-
treated group was more than 10 years. Additionally, they
were able to lose weight: initial results at three months
were maintaining until the end of the study. The negative
effect on cardiovascular risk factors such as cholesterol
that is frequently claimed as a risk of low-carbohydrates
was not found in this study. There was no significant
change in cholesterol, HDL-cholesterol and LDL-choles-
terol during the course of the study.
H b A 1 cd e c l i n e di nt h ef i r s t4w e e k sb y1 3 %w h e r e a s
body weight declined only by 5%. At week 8, HbA1c had
already reached its final reduction of 23% comparable to
26% at week 24. By comparison, body weight declined 6%
at week 8 and had reached 13% at week 24. Because
HbA1c is the average of glucose concentrations during the
previous 3 months, the large drop within the first 4 weeks
is not seen in this slowly reacting parameter and reflects
an abrupt improvement and normalization of glucose con-
centrations. This largely weight- independent improve-
ment in metabolic control is in line with previous work
showing that weight change and glycemic control are not
serially linked [12,21].
Patients were very satisfied with this treatment option.
They were able to understand the detrimental effect on
their metabolism of carbohydrates with high glycemic
index and to make reasonable food choices in the future.
All patients were willing to continue with this treatment
option and did not have the feeling of being on a diet.
Most of the patients had had diabetes for quite a long
Figure 3 Time course of HbA1c split by pretreatment. This figure displays the drop of HbA1c during the intervention at all visits until the
end of the study at 6 months split by pretreatment (Insulin versus Oral Antidiabetic Drugs).
Table 3 Results at 24 weeks split by pretreatment
Whole Group n = 40 Insulin Group n = 16 OAD † Group n = 24
Mean Std Mean Std Mean Std
HbA1c 6.7 0.8 6.7 0.7 6.7 0.9
Body weight, kg 101.3 17.8 94.7 17.5 105.3 17.1
Cholesterol 193.0 32.7 183.4 28.4 197.4 34.2
Triglycerides 198.8 99.6 177.0 57.0 208.7 104.5
HDL-cholesterol 54.0 17.6 56.3 10.8 53.0 20.1
LDL-cholesterol 101.8 29.3 96.2 24.4 104.6 31.7
†OAD: Oral Antidiabetic Drug
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chance to lose weight.
Limitations of our study include the absence of a control
group, patients either treated conventionally with intensi-
fied insulin treatment or with carbohydrate-restricted diet
or metformin or liraglutide alone. Due to limited time,
logistic and funding resource, this study design was not
possible. Drop-out rate was quite low, but was not zero.
This may give rise to the possibility of bias in favor of
treatment effects. In addition, no food frequency
questionnaires were taken during the time course of the
study. We are not sure that two patients who showed an
upward trend of their HbA1c at 6 months really followed
t h ep r i n c i p l eo ft h ed i e t( F i g u r e2 ) .O u rs t u d yw a sp e r -
formed in an outpatient setting in the world of private
praxis. For logistic reasons laboratory measurements could
not be done centrally. Each office had its method for run-
ning the analysis. With respect to HbA1c the current
international standard will make measurements between
offices comparable. Beyond the proof-of-principle, which
showed a remarkable treatment effect, this study is able to
do power calculation for further randomized trials com-
paring this novel method with standard treatment.
The beneficial effect of low-carbohydrate diets on glu-
cose metabolism in patients with type 2 diabetes will
enable reduction in medication. This applies as well to
anti-hypertensive drugs, which were also often reduced.
Especially noteworthy is this treatment option for patients
with short duration of diabetes. Even patients with newly
diagnosed diabetes type 2 showing HbA1c values around
9% can be treated with low-carb diets alone or in conjunc-
tion with metformin. In our study most patients had a
long lasting disease and had been treated for several years
Figure 4 Trajectories of Triglycerides in individual patients. The pattern in this figure is concerned with individual changes of Triglycerides
during the intervention. Each line displays the individual change of Triglycerides.
Table 4 Treatment satisfaction
Score
1† 234 5 6 7 ‡
Treatment satisfaction overall 0 0 0 0 5 10 25
Satisfaction with weight 0 0 0 4 6 15 18
Satisfaction with blood glucose 0 0 1 2 8 13 19
Avoidance of carbohydrates 1 1 2 9 10 15 5
Maintaining new therapy 0 0 0 4 7 11 18
Permanent reduction of carbohydrates 0 0 0 2 7 15 16
†1 = strongly disagree
‡7 = completely agree
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fat diets with high complex carbohydrate, but had been
unable to achieve metabolic control. Switching to this
alternative diet regimen was seen as providing relief.
Conclusions
In summary, dietary carbohydrate restriction in conjunc-
tion with metformin and liraglutide treatment is an effec-
tive treatment option for patients with advanced diabetes
who are scheduled to switch to insulin or who are in
need of intensified insulin treatment to regain metabolic
control. During this 24-week outpatient proof-of-princi-
ple study, patients showed a significant treatment effect
with a majority of patients reaching HbA1c-values below
7%. The treatment effect shown will form the basis for
further power calculation for a randomized intervention
trial comparing this new treatment option with standard
methods.
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